Literature DB >> 7539030

A role for C-C chemokines in fibrotic lung disease.

R E Smith1, R M Strieter, K Zhang, S H Phan, T J Standiford, N W Lukacs, S L Kunkel.   

Abstract

Pulmonary fibrosis is the end point of a chronic inflammatory process characterized by leukocyte recruitment and activation, fibroblast proliferation, and increased extracellular matrix production. Previous studies of models of pulmonary fibrosis have investigated the role of cytokines in the evolution of the fibrotic response. The involvement of tumor necrosis factor and interleukin-1 in bleomycin-induced lung injury, a model of idiopathic pulmonary fibrosis, has been well established, suggesting that cytokines mediate the initiation and maintenance of chronic inflammatory lesions. However, the aforementioned cytokines alone cannot account for the recruitment and activation of specific leukocyte populations found in the bleomycin model. Recently, a family of novel proinflammatory cytokines (chemokines) was cloned and characterized, yielding many putative mediators of leukocyte functions. Macrophage inflammatory protein-1 alpha (MIP-1 alpha) and monocyte chemoattractant protein-1 (MCP-1) belong to the C-C chemotactic cytokine family, a group of low-molecular-weight peptides. These molecules modulate chemotaxis, proliferation, and cytokine expression in leukocyte subsets. Our group has investigated the roles of MCP-1 and MIP-1 alpha in the bleomycin model. Both MCP-1 and MIP-1 alpha are expressed in a time-dependent manner after bleomycin challenge, and passive immunization of these animals with either anti-MIP-1 alpha or anti-MCP-1 antibodies attenuated leukocyte accumulation. In addition, we have identified specific cell types expressing MCP-1 or MIP-1 alpha by in situ hybridization and immunohistochemical localization, respectively. Furthermore, our results indicate that MIP-1 alpha expression is mediated by alveolar macrophage-derived tumor necrosis factor, identifying an important cytokine pathway in the initiation of pulmonary fibrosis. Finally, anti-MIP-1 alpha therapy attenuated fibrosis, providing direct evidence for its involvement in fibrotic pathology. Our work has clearly established that the C-C chemokines MCP-1 and MIP-1 alpha are expressed and contribute to the initiation and maintenance of the bleomycin-induced pulmonary lesion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539030     DOI: 10.1002/jlb.57.5.782

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  47 in total

1.  FTS reduces bleomycin-induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice.

Authors:  S Yara; K Kawakami; N Kudeken; M Tohyama; K Teruya; T Chinen; A Awaya; A Saito
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 2.  Disorders of lung matrix remodeling.

Authors:  Harold A Chapman
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 3.  Fibrotic disease and the T(H)1/T(H)2 paradigm.

Authors:  Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

4.  Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis.

Authors:  A R Glabinski; M Tani; R M Strieter; V K Tuohy; R M Ransohoff
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

5.  Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-ERK1/2-mediated mechanism in primary human lung fibroblasts.

Authors:  Pedro A Ruiz; Gabor Jarai
Journal:  J Biol Chem       Date:  2011-02-18       Impact factor: 5.157

6.  Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis.

Authors:  Yasuhito Hamaguchi; Yoriko Nishizawa; Masahide Yasui; Minoru Hasegawa; Yuko Kaburagi; Kazuhiro Komura; Tetsuya Nagaoka; Eriko Saito; Yuka Shimada; Kazuhiko Takehara; Takafumi Kadono; Douglas A Steeber; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

7.  Gene transfer of soluble transforming growth factor type II receptor by in vivo electroporation attenuates lung injury and fibrosis.

Authors:  Mizuho Yamada; Kazuyoshi Kuwano; Takashige Maeyama; Michihiro Yoshimi; Naoki Hamada; Jutaro Fukumoto; Kensuke Egashira; Kenichi Hiasa; Koichi Takayama; Yoichi Nakanishi
Journal:  J Clin Pathol       Date:  2006-10-03       Impact factor: 3.411

8.  Targeted delivery of YSA-functionalized and non-functionalized polymeric nanoparticles to injured pulmonary vasculature.

Authors:  Madhoosudan A Patil; Arun K Upadhyay; Laura Hernandez-Lagunas; Ryan Good; Todd C Carpenter; Carmen C Sucharov; Eva Nozik-Grayck; Uday B Kompella
Journal:  Artif Cells Nanomed Biotechnol       Date:  2018-11-19       Impact factor: 5.678

Review 9.  Cellular and molecular mechanisms of fibrosis.

Authors:  T A Wynn
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

10.  Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.

Authors:  Katrin Schmidt; Lorena Martinez-Gamboa; Susan Meier; Christian Witt; Christian Meisel; Leif G Hanitsch; Mike O Becker; Doerte Huscher; Gerd R Burmester; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-07-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.